MedTrace Logo

Arimidex/Faslodex/Iressa Study: A Trial Using Arimidex, Faslodex and Iressa in Women With Breast Cancer

NCT00206414 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2013-02-05

No results posted yet for this study

Summary

The investigators want to know if combining Arimidex and Faslodex with Iressa will be an effective treatment for breast cancer. They also want to know, using special tests on the tumor, the changes that occur with the treatment so they can try to improve their treatment for breast cancer in the future.

Conditions

Interventions

DRUG

Iressa Day 1 given with Arimidex and Faslodex

timing of administration of iressa is the study factor

DRUG

Iressa Day 21 given with Arimidex and Faslodex

Timing of Iressa is the study factor

Sponsors & Collaborators

  • Baylor Breast Care Center

    lead OTHER

Principal Investigators

  • Mothaffar Rimawi, MD · Baylor Breast Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-01-31
Primary Completion
2006-09-30
Completion
2006-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00206414 on ClinicalTrials.gov